EP2146699A2 - Pharmazeutische zusammensetzungen mit oxcarbazepin - Google Patents

Pharmazeutische zusammensetzungen mit oxcarbazepin

Info

Publication number
EP2146699A2
EP2146699A2 EP08758478A EP08758478A EP2146699A2 EP 2146699 A2 EP2146699 A2 EP 2146699A2 EP 08758478 A EP08758478 A EP 08758478A EP 08758478 A EP08758478 A EP 08758478A EP 2146699 A2 EP2146699 A2 EP 2146699A2
Authority
EP
European Patent Office
Prior art keywords
oxcarbazepine
pharmaceutical composition
composition according
total weight
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08758478A
Other languages
English (en)
French (fr)
Inventor
Satish G. Dhonde
Ganesh V. Gat
Jawed Hussain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ratiopharm GmbH
Original Assignee
Ratiopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm GmbH filed Critical Ratiopharm GmbH
Publication of EP2146699A2 publication Critical patent/EP2146699A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Definitions

  • compositions comprising Oxcarbazepine
  • the present invention relates to a pharmaceutical composition comprising Oxcarbazepine.
  • Oxcarbazepine 10,11-dihydro-10-oxo-5H-dibenzo(b,f)azepine-5-carboxamide, is an anticonvulsant and mood stabilizing drug, used primarily in the treatment of epilepsy and bipolar disorders.
  • Oxcarbazepine has the following chemical structure:
  • Oxcarbazepine is known in dosage forms, such as tablets and liquid dosage forms, e.g. suspensions, which are suitable for ensuring a uniform concentration of active ingredient in the blood, especially in the case of regular adminstration over a prolonged period of treatment.
  • Oxcarbazepine is only poorly soluble in water.
  • WO 02/094774 A2 discloses a dosage form composition for oral adminstration comprising Oxcarbazepine and a wetting agent.
  • the use of the wetting agent in the formulation may show enhanced dissolution rates in the in-vitro conditions, but an effectivity in-vivo has not been shown yet. Further the use of a wetting agent in pharmaceutical compositions is disadvantageous.
  • a pharmaceutical composition which comprises Oxcarbazepine in the form of particles with a mean particle size of about 2 ⁇ m or less and contains not more than about 7 wt.%, preferably not more than 5 wt.%, more preferably not more than about 2 wt.% of a binder, based on the total weight of the composition, dissolves quickly without the need of a wetting agent.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising about 20-90 wt.% of Oxcarbazepin or a pharmaceutically acceptable salt thereof as active ingredient, based on the total weight of the composition, the Oxcarbazepine being in the form of particles, wherein the median particle size of the Oxcarbazepine particles is about 2 ⁇ m or less and the composition does not contain more than about 7 wt.%, preferably not more than 5 wt.%, more preferably not more than about 2 wt.% of a binder, based on the total weight of the composition.
  • WO 02/094774 generally suggests to use a wetting agent, as without a wetting agent a desired dissolution profile of Oxcarbazepine tablets would not be obtained. It is further suggested to reduce the median particle size below 10 ⁇ m for getting a desired dissolution profile. However, the desired dissolution profile could only be obtained for mean particle sizes of 10 ⁇ m and 9 ⁇ m. Reduction of the mean particle size to 1 ,5 ⁇ m provided a tablet containing Oxcarbazepine showing a rather poor dissolution profile.
  • the present invention provides pharmaceutical compositions comprising Oxcarbazepine as active ingredient, wherein the Oxcarbazepine particles have a median particle size of about 2 ⁇ m or less and the composition does not contain more than about 7 wt.%, preferably not more than 5 wt.%, more preferably not more than about 2 wt.% of a binder.
  • Such compositions show to have, contrary to the compositions disclosed in WO 02/094774 lacking a wetting agent, an excellent, quick dissolution of the active ingredient, in particular a dissolution profile such that at least 80 wt.% or more of the active ingredient contained in the tablet is dissolved within 15 minutes without using a wetting agent.
  • the pharmaceutical composition according to the present invention contains not more than about 7 wt.%, preferably not more than 5 wt.%, more preferably not more than about 2 wt.% of a binder, based on the total weight of the composition, even more preferably not more than about 1.5 wt.%, in particular not more than about 1 wt.% of a binder.
  • Binders to be used in the compositions of the present invention are such binders known in the art, i.e. compounds which have cohesive properties to act as binders, in particular hydroxypropylmethyl celluloses, hydroxypropyl celluloses (HPC), polyvinyl pyrrolidone (PVP), starches and modified starches.
  • binders e.g. cross-linked polyvinyl pyrrolidone, which can be used as disintegrant and binder, is regarded, according to the present invention, as a binder.
  • compounds which can also be used as excipients or adjuvants different to binders, such as disintegrants, or diluents are, according to the present invention, not regarded as binders, but as disintegrants and diluents, respectively (e.g. cross-linked polyvinyl pyrrolidone is regarded as disintegrant only).
  • the pharmaceutical compositions of the present invention generally comprise Oxcarbazepine as active ingredient, in particular about 20-90 wt.%, based on the total weight of the composition, preferably about 50-80 wt.%, in particular about 60-78 wt.%, e.g. about 73 wt.%.
  • the Oxcarbazepine is in the form of particles and the median particle size of the Oxcarbazepine is about 2 ⁇ m or less, such as about 1.5 ⁇ m or less or about 1 ⁇ m or less.
  • the Oxcarbazepine particles have a narrow particle size distribution being defined by the ratio between the median particle size and the particle size at the 95% quantile. This ratio can be equal to or greater than about 0.4, preferably greater than about 0.45, more preferably greater than about 0.5 and most preferably between about 0.55 and about 0.7, such as for example about 0.60 ⁇ 0.02.
  • particle size distribution means the cummulative volume size distribution of equivalent spherical diameters as determined by laser diffraction in accordance with ISO 13320, preferably at 1.0 bar dispersive pressure in a MASTERSIZER 2000 (Malvern Instruments) equipment in particular as described in Example 4.
  • Median particle size correspondigly, means the median of said particle size distribution (d(0.5) or X 50 (ISO 13320)); d(0.1) corresponds to X 10 (ISO 13320) and d(0.9) corresponds to X 90 (ISO 13320).
  • the pharmaceutical composition of the present invention may further comprise suitable pharmaceutically acceptable excipients and adjuvants, such as diluents, disintegrants, glidants, lubricants, and/or film formers/film coating agents.
  • suitable pharmaceutically acceptable excipients and adjuvants such as diluents, disintegrants, glidants, lubricants, and/or film formers/film coating agents.
  • diluents mannitol, lactose, starch and microcrystalline cellulose can be exemplified.
  • the pharmaceutical composition of the present invention contains about 0-80 wt.% of a diluent, preferably about 10-20 wt.% of a diluent, more preferably about 14-18 wt.% of a diluent, in particular about 17 wt.%, based on the total weight of the composition.
  • Disintegrants preferred for the pharmaceutical composition of the present invention may be selected, as far as they are regarded as disintegrants according to the above definition, from starches or modified starches such as sodium starch glycolate, corn starch, potato starch or pregelatinized starch, celluloses such as microcrystalline celluloses, carboxymethyl celluloses, such as modified sodium carboxymethyl celluloses, algines such as sodium alginate or alginic acid, crosslinked celluloses such as crosscarmellosodium, gums such as guar gum or xanthan gum, crosslinked polymers such as crosspovidone, and effervescent agents such as sodium bicarbonate and citric acid, and mixtures thereof.
  • starches or modified starches such as sodium starch glycolate, corn starch, potato starch or pregelatinized starch
  • celluloses such as microcrystalline celluloses, carboxymethyl celluloses, such as modified sodium carboxymethyl celluloses
  • algines such as sodium alginate or alginic acid
  • the pharmaceutical composition of the present invention preferably contains about 0-20 wt.% of a disintegrant, more preferably about 2-8 wt.% of a disintegrant, even more preferably about 4-6 wt.% of a disintegrant, in particular about 5 wt.% of a disintregrant, based on the total weight of the composition.
  • glidants to be used in the pharmaceutical composition of the present invention talc and colloidal silicone dioxide can be exemplified.
  • the pharmaceutical composition of the present invention preferably contains about 0-2 wt.% of a glidant, more preferably about 0.1-1 wt.% of a glidant, in particular about 0.6 wt.% of a glidant, based on the total weight of the composition.
  • the pharmaceutical composition of the present invention may further contain a lubricant such as talc or magnesium stearate, or other alkali earth metal stearates like calcium, zinc etc., lauryl sulphate, hydrogenated vegetable oil, sodium benzoate, sodium stearyl fumarate, glyceryl monostearate and a polyethylenglycol, such as PEG 4000.
  • a lubricant such as talc or magnesium stearate, or other alkali earth metal stearates like calcium, zinc etc., lauryl sulphate, hydrogenated vegetable oil, sodium benzoate, sodium stearyl fumarate, glyceryl monostearate and a polyethylenglycol, such as PEG 4000.
  • the pharmaceutical composition of the present invention contains about 0-2 wt.% of a lubricant, more preferably about 0.5-1.5 wt.% of a lubricant, in particular about 1 wt.% of
  • the pharmaceutical composition of the present invention may further contain a film former, which is preferably applied as the film coating on a solid form of the pharmaceutical composition.
  • a film former is preferably based on hydroxypropylmethyl cellulose (HPMC) and/or on polyvinyl alcohol (PVA).
  • HPMC hydroxypropylmethyl cellulose
  • PVA polyvinyl alcohol
  • the film former is preferably contained in the pharmaceutical composition of the present invention in an amount of about 0-5 wt.%, more preferably about 1-4 wt.%, in particular about 3 wt.%, based on the total weight of the composition, and is preferably applied as a film coating onto the solid forms of the pharmaceutical composition.
  • the pharmaceutical composition of the present invention contains about 0-20 wt.% of a diluent, about 0-10 wt.% of a disintegrant, about 0-2 wt.% of a glidant, about 0-2 wt.% of a lubricant, and about 0-5 wt.% of a film former, each based on the total weight of the composition.
  • the ingredients of the pharmaceutical composition have to sum up to 100 wt.%.
  • composition of the present invention may comprise various other conventional excipients as known to the person skilled in the art, such as colouring agents or sweeteners.
  • the pharmaceutical composition according to the present invention is in the form of a solid pharmaceutical composition, such as a capsule or a tablet, the latter being particularly preferred. Even more preferable the pharmaceutical composition is a film coated tablet. Preferably such a tablet shows a dissolution profile such that about 80 wt.% or more of the active ingredients contained in the tablet is dissolved within 15 minutes.
  • the term "dissolution profile" within this application means the variation in time of the amount of active ingredient, which is dissolved, based on the total amount of this ingredient contained in the solid pharmaceutical composition.
  • the dissolution profile is obtained by dissolving a tablet in an USP apparatus Il in 900 ml water containing 1% SDS (sodiumdodecylsulphate) at 37 0 C under stirring (paddle) with a stirring speed of 60 rpm, and the amount of active ingredient is detected over a range of time, such as 45 minutes at different points of time, e.g. after 5, 10, 15, 20, 30 and 45 minutes.
  • the solid preparation composition of the present invention may be prepared by conventional methods as known to those skilled in the art.
  • the tablets may be prepared by conventional tabletting methods.
  • the tablets are prepared by granulating, preferably wet granulation.
  • the active ingredient together with any excipient may be filled into capsules, such as hard gelatin capsules by conventional methods, for example using a capsule filler suitable for powder filling.
  • the solid pharmaceutical compositions of the present invention compressed as tablets are in a unit dosage form comprising about 150, 300 or 600 mg of Oxcarbazepine.
  • the tablets prepared from the pharmaceutical composition comprising Oxcarbazepine according to the present invention exhibit a dissolution profile being very similar to the dissolution profile of the commercially available Trileptal ® tablets (Novartis Germany).
  • the present invention also relates to a process for the preparation of a pharmaceutical composition according to the present invention comprising mixing the Oxcarbazepine or pharmaceutically acceptable salt thereof being in the form of particles, which preferably have a median particle size of about 2 ⁇ m or less, with the pharmaceutically acceptable excipients and adjuvants, and preparing a solid pharmaceutical composition, preferably a tablet from said mixture, which is optionally film coated.
  • the present invention relates to the use of Oxcarbazepine or a pharmaceutically acceptable salt thereof in the form of particles having a median particle size of about 2 ⁇ m or less for the preparation of a pharmaceutical composition according to the present invention.
  • a dissolution profile of the tablets of example 1 is shown in Figure 1.
  • a dissolution profile of the tablets of example 2 is shown in Figure 2.
  • the following examples are merely intended to illustrate the invention and should not be construed as limiting.
  • Oxcarbazepine film coated tablets containing 150, 300 and 600 mg of Oxcarbazepine
  • the coating composition is the same except for the use of different colors e.g.
  • Oxcarbazepine Microcrystalline cellulose (Avicel PH 101) and Hydroxypropyl methyl cellulose (Methocel E5 LV) in a mixer (High shear mixer granulator) and dry mix to ensure adequate mixing;
  • Oxcarbazepine film coated tablets containing 150, 300 and 600 mg of Oxcarbazepine
  • the coating composition is the same except for the use of different colors e.g.
  • Oxcarbazepine Microcrystalline cellulose (Avicel PH 101) and Hydroxypropyl methyl cellulose (Methocel E5 LV) in a mixer (High shear mixer granulator) and dry mix to ensure adequate mixing;
  • Coating compositions for Oxcarbazepine film coated tablets containing 150, 300 and
  • Particle size determination (PSD) method Particle size determination (PSD) method:
EP08758478A 2007-05-23 2008-05-13 Pharmazeutische zusammensetzungen mit oxcarbazepin Withdrawn EP2146699A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1078CH2007 2007-05-23
PCT/EP2008/003814 WO2008141751A2 (en) 2007-05-23 2008-05-13 Pharmaceutical compositions comprising oxcarbazepine

Publications (1)

Publication Number Publication Date
EP2146699A2 true EP2146699A2 (de) 2010-01-27

Family

ID=39679291

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08758478A Withdrawn EP2146699A2 (de) 2007-05-23 2008-05-13 Pharmazeutische zusammensetzungen mit oxcarbazepin

Country Status (2)

Country Link
EP (1) EP2146699A2 (de)
WO (1) WO2008141751A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014143935A1 (en) * 2013-03-15 2014-09-18 Aprecia Pharmaceuticals Company Rapidly dispersible dosage form of oxcarbazepine
WO2015063670A1 (en) * 2013-10-30 2015-05-07 Wockhardt Limited Solid oral modified-release composition comprising oxcarbazepine or a pharmaceutically acceptable salt thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
CN1522140A (zh) * 2001-05-18 2004-08-18 兰贝克赛实验室有限公司 奥卡西平剂型
WO2007089247A1 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008141751A3 *

Also Published As

Publication number Publication date
WO2008141751A3 (en) 2009-07-16
WO2008141751A2 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
JP4785847B2 (ja) プラミペキソール又はその医薬品として許容される塩を含む放出が延長された錠剤調合物、その製造方法及びその使用
JP2009108064A (ja) ５，７，１４−トリアザテトラシクロ［１０．３．１．０２，１１．０４，９］−ヘキサデカ−２（１１），３，５，７，９−ペンタエンの医薬組成物
NO331689B1 (no) Oral farmasoytisk sammensetning omfattende rivastigmin, samt anvendelse av rivastigmin
WO2006022996A2 (en) Dosage form containing multiple drugs
AU2003229705A1 (en) High drug load tablet
US6048547A (en) Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient
KR20070115918A (ko) 멀티플 유닛형 경구 서방성 제제 및 그 제조방법
US20100151018A1 (en) Sustained-release levetiracetam composition and preparation process
JPH09500910A (ja) パラセタモール及びドンペリドンのフィルムコーティング錠
HUE031251T2 (en) Controlled release oral dosage form containing oxycodone
US11382912B2 (en) Controlled-release preparation
JP3182423B2 (ja) シサプリドの経口用徐放性組成物
JP5124286B2 (ja) 徐放性製剤およびその製造方法
WO2006123213A1 (en) Modified release formulations of gliclazide
EP2481397A1 (de) Pharmazeutische Zusammensetzungen mit Tasocitinib
JP5420126B2 (ja) ｐＨ非依存延長放出性医薬組成物
WO2013121233A1 (en) Pharmaceutical formulation having improved stability
US20110300209A1 (en) Modified release solid pharmaceutical compositions of trimetazidine and process thereof
WO2004096182A1 (en) Extended release matrix tablets of carvedilol
WO2008141751A2 (en) Pharmaceutical compositions comprising oxcarbazepine
WO2009043914A1 (en) Multi particulate matrix system containing galantamine
EP2097071A1 (de) Pharmazeutische zusammensetzung von memantin
CA2642414C (en) Rapid release irbesartan-containing pharmaceutical composition
JP5245175B2 (ja) 持続放出型錠剤の製造方法
WO2018130943A1 (en) Oral pharmaceutical composition of lurasidone and preparation thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091109

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

17Q First examination report despatched

Effective date: 20100318

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100929